Extending Hepatitis C Treatment in Post-Liver Transplant Patients May Prove Beneficial

A new study has shown that extending hepatitis C treatment for liver transplant patients beyond current standards results in high clearance rates of the hepatitis

A new study has shown that extending hepatitis C treatment for liver transplant patients beyond current standards results in high clearance rates of the hepatitis C virus from the blood, and a low relapse rate.

"We found that patients who achieved a sustained virological response were more likely to have had extended treatment after transplant," said Matthew Moeller, gastroenterology fellow at Henry Ford Hospital and lead author of the study.

Good News For Hepatitis C Patients
Telaprevir, a protease inhibitor, combined with standard hepatitis C treatment, cures a significantly higher number of difficult-to-treat patients than standard treatment alone, a new study has found.

"In the study, we saw a trend toward decreased mortality as sustained virological response was found to be associated with a 100 percent five-year survival rate vs. 86 percent for those without," Moeller added.

Although, statistically insignificant, the trend could show significance with longer follow-up and a larger sample size, said Moeller.

As part of the study, the researchers looked at 241 consecutive liver transplant patients from 1999-2006. Patients were offered treatment if they tested positive for hepatitis C, had recurrent hepatitis C with at least Stage I fibrosis on biopsy, and stable immunosuppression for a minimum of three months.

Hepatitis C Patients More at Risk of Developing Kidney Cancer: Study
Infection with the hepatitis C virus increases the risk for developing kidney cancer, physicians at Henry Ford Hospital have found.

Patients received either non-pegylated interferon tiw or pegylated interferon weekly in combination with ribavirin.

Of the study patients with hepatitis C, 66 were eligible for treatment, and 22 achieved sustained virological response. Only two patients (8 percent) relapsed.

Structure-based Design of New Hepatitis C Treatment Identified
The binding of a potent inhibitor of the hepatitis C virus (HCV) to the genetic material of the virus causes a major conformational change that may adversely affect the ability of the virus

This is in contrast to typical relapse rates of 30-35 percent in non-transplant patients treated with standard therapy. Genotype 1 patients failed more than genotype 2 or 3 patients in achieving sustained virological response (27 percent vs. 70 percent).

Dr. Moeller noted that 35 percent of patients who went on to achieve sustained virological response first became virus-negative at or following week 24.

Hepatitis C Can Also Make You Vulnerable To Diabetes
Those contracting Hepatitis C could also be more vulnerable to type 2 diabetes, by as much as three to four times, Australian study reveals.

"Our results suggest that even if patients are positive at week 24, there is still a 35 percent chance that they can achieve sustained viral clearance with extended treatment," said Dr. Moeller.

The results of the study were presented at the Digestive Diseases Week conference in New Orleans.

Source-ANI
TAN